Medical Device CDMO Accelerates Innovation with Sharply Reduced Costs and No Need for In-House Manufacturing Facilities

The Medical Device Registrant System, which began as a pilot program in the Shanghai Free Trade Zone in 2017, expanded to 21 provinces, autonomous regions, and municipalities directly under the Central Government by 2019, and was formally incorporated into the industry’s overarching legal framework—the Regulations on the Supervision and Administration of Medical Devices (2021 Revision)—in 2021, has now been in place for six full years. After six years of incubation, accumulation, and rapid growth, the Medical Device Registrant System is finally exerting its maximum influence and driving the development of China’s medical device industry.

In recent years, the domestic medical device CDMO industry has developed rapidly. A number of CDMO companies in different niche fields are continuously growing, emerging, and empowering the development of the medical device industry, demonstrating significant potential for industry growth.

Medical device CDMO is one of the primary types of outsourced services in the medical device industry. It refers to enterprises that provide process research and development, design, and manufacturing services to medical device R&D entities through contractual agreements. These services help medical device companies mitigate risks, reduce costs associated with R&D and production, and accelerate time-to-market for their products.

Currently, multiple medical device CDMO platforms in China are operating stably, and a number of healthcare innovation enterprises have adopted the CDMO model, offering positive evaluations of this approach.Then

To explore these questions,February 22 (Wednesday) 20:00, hosted by VCBeat"Medical Device CDMO Special Report" Issue 1,Inviting Cao Changqing, Founder & General Manager of Juyi Technology; Tan Long, Sales Director for East China at Daishengsi Medical; and Wang Haihua, Investment Director at Legend Capital“Significant Cost Reduction and No Need for Self-Built Facilities: CDMOs Accelerate Medical Device Innovation” as the Main Topic Direction,Let’s delve into the aforementioned issues.

Live Stream Registration: Scan the QR Code on the Poster

Scan the QR code to add our assistant and join the industry exchange group.

Cao Changqing | Founder and General Manager of Juyi Technology

With over 20 years of experience in the productization of professional medical devices and CDMO technical services, previously held positions at Philips and Jabil Healthcare, serving as the Asia-Pacific Regional Manager for Medical Business and Technical Management.

Tan Long | Sales Director, East China Region, Daishengsi Medical

Tan Long, Sales Director for East China at Daishengsi Medical, has cultivated extensive expertise in the pharmaceutical and medical device industries. He has established CDMO partnerships with multiple leading enterprises in the region concerning interventional consumables, with a particular focus on deep collaboration in electrophysiology mapping catheters, electrophysiology ablation catheters, and disposable electronic endoscopes.

Wang Haihua | Investment Director, Legend Capital

Wang Haihua, a Chinese Certified Public Accountant (CPA) and MBA graduate of London Business School, currently serves as Investment Director at Legend Capital. He focuses on investments in healthcare services, medical supply chains, CRO/CMO, and consumer healthcare. Projects he has led or participated in include Aidite, Juyi Technology, Elios, Xihua Testing, Saifu Pharmaceuticals, Lingfu Biologics, Liuhe Ningyuan, Shengsheng Logistics, Zhixiang Biologics, BioDuro, and Sansong Medical.

Juyi Technology is one of the industry-leading professional platforms for contract research, development, and manufacturing (CDMO) of innovative medical devices. It currently provides a comprehensive suite of outsourced R&D, clinical, and manufacturing services to over 50 global biopharmaceutical companies, medical device manufacturers, and clinical and research institutions. Its service offerings cover the entire product lifecycle, from initial innovation concepts and technical research, collaborative product development, and supply chain management, to contract manufacturing, clinical trials, regulatory registration, and commercial launch.

Daishengsi Medical is dedicated to the independent R&D of ultra-miniature sensors specialized for medical devices, including pressure, temperature, magnetic positioning, and flow rate sensors. The company provides systematic solutions for sensor integration within compact volumes and complex assembly structures.

The company offers customized sensor solutions and provides end-to-end contract design and manufacturing organization (CDMO) services, including product-assisted design, prototyping, and mass production. It has extensive experience in active interventional products such as high-density mapping catheters, ablation catheters, ultrasound catheters, endoscopes, and urological catheters.

The company has established an R&D center in Shenzhen and operates a 5,500-square-meter Class 7 (10,000-grade) cleanroom production base in Dongguan and Taizhou, Zhejiang. Compliant with FDA/GMP standards and certified under the ISO 13485 quality management system, the company delivers products and services of international caliber, empowering the intelligent upgrade of the minimally invasive interventional device industry.

Legend Capital, established in April 2001, is a fund management company under Legend Holdings that specializes in early-stage venture capital and growth-stage private equity investments. Over the past two decades, Legend Capital has adhered to international standards, creating best practices in fund operations and management. Through its proactive value-added service system, it drives innovative corporate growth, consistently delivering strong investment returns across multiple sectors while advancing China’s industrial progress and social development. With the vision of “becoming an investment firm with global influence,” Legend Capital upholds the core value of “Prosperity with Integrity” and actively fulfills its social responsibilities.

Legend Capital has long focused on investments in the medical device and diagnostics sectors, having invested in a series of leading companies across various niche segments within these fields.

VCBeat, founded in 2014, is China’s leading research and media platform for the healthcare industry. Leveraging its five major brands—VCBeat (which includes VCBeat New Medicine and VCBeat Orange Outcome Bureau), Eggshell Research Institute, VB100, VCBeat Orange, and 35Dou—as well as Eggshell Capital, it has established business segments encompassing media communication, industry research, brand events, investment and financing, and industrial resource matchmaking. These services provide innovation acceleration support to innovative enterprises, large corporations, government industrial parks, and other stakeholders.

“VB ThinkShare” is one of VCBeat’s flagship events, serving as a face-to-face platform centered on exploring solutions in the healthcare sector, with the aim of “focusing on practical challenges and discussing industry trends.” The event conducts in-depth discussions, analyses, and idea exchanges on the current state of development around core themes, addressing encountered difficulties, pain points, and barriers. Meanwhile, it gains deep insights into the resource endowments of participating enterprises, fostering practical collaborations through intellectual exchange.